

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of modulating ~~a biological function of an endothelial cell or hematopoietic T-cell~~ activation, comprising introducing in vitro ~~into the cell~~ an agent that inhibits binding of ~~a PDZ protein and a PL protein~~ LPAP and TIP-1 ~~in the~~ into a T-cell, thereby modulating activation of the T-cell, ~~the biological function~~, wherein

——— ~~the PL is LPAP and~~

——— ~~the PDZ is TIP1.~~

2-4. (Canceled)

5. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the agent is a peptide that (i) is 4- 25 amino acids in length and (ii) comprises ~~comprising~~ a sequence of at least the carboxy-terminal two residues of ~~the PL protein~~ LPAP.

6. (Currently amended) The method of ~~claim 4~~ claim 5, wherein the agent is a peptide comprising a sequence of at least the carboxy-terminal three residues of ~~the PL protein~~ LPAP.

7. (Currently amended) The method of ~~claim 1~~ claim 1, wherein the agent is a small molecule or peptide mimetic of the carboxy-terminus of ~~the PL protein~~ LPAP.

8-20. (Canceled)

21. (New) The method of claim 5, wherein the peptide is 12-25 amino acids in length.